LSBCF (LakeShore Biopharma Co) Shareholder Yield % : 464.11% (As of Mar. 2025)


What is LakeShore Biopharma Co Shareholder Yield %?

LakeShore Biopharma Co LSBCF Shareholder Yield % is 464.11% as of Mar. 2025. The stock has 5 warning signs investors should review. Among 1,301 Biotechnology companies, LakeShore Biopharma Co ranks better than 99.77% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, LakeShore Biopharma Co's Shareholder Yield % was 464.11%.


LakeShore Biopharma Co  (OTCPK:LSBCF) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


LakeShore Biopharma Co Shareholder Yield % Related Terms


LakeShore Biopharma Co Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Shareholder Yield % Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Shareholder Yield %
0.00 0.00 -6.09 -27.64 25.19

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only -6.09 -15.15 -27.64 14.32 25.19

LSBCF vs ACUT, PPCB, ENSC: Shareholder Yield % Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Shareholder Yield % falls into.



LakeShore Biopharma Co Shareholder Yield % Calculation

LakeShore Biopharma Co's Shareholder Yield % for the quarter that ended in Mar. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+25.19 %
=25.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 464.11% mean?
LakeShore Biopharma Co (LSBCF) has a Shareholder Yield % of 464.11% as of Mar. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on LakeShore Biopharma Co and its competitors. According to the industry distribution chart, LakeShore Biopharma Co ranks #3 out of 1301 companies in the Biotechnology industry, placing it in the top 0.2%.
Is LakeShore Biopharma Co's Shareholder Yield % too high?
LakeShore Biopharma Co's current Shareholder Yield % is 464.11%. Based on the distribution chart, LakeShore Biopharma Co ranks #3 out of 1301 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does LakeShore Biopharma Co's Shareholder Yield % compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #3 out of 1301 companies for Shareholder Yield %. This places LakeShore Biopharma Co in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Shareholder Yield % is 464.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Shareholder Yield % of 464.11%. The current Shareholder Yield % is 464.11%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Shareholder Yield % is 464.11% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.